Cargando…

Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer

SIMPLE SUMMARY: The addition of chromosome 17 polysomy/HER2 amplification status to the updated EAU and AUA scores improves their accuracy, allowing molecular reclassification of EAU high-risk NMIBCs and G2 tumors. Based on this, we propose to reclassify the non-HER2 amplified, non-polysomic EAU 3–4...

Descripción completa

Detalles Bibliográficos
Autores principales: Kocsmár, Ildikó, Kocsmár, Éva, Pajor, Gábor, Kulka, Janina, Székely, Eszter, Kristiansen, Glen, Schilling, Oliver, Nyirády, Péter, Kiss, András, Schaff, Zsuzsa, Riesz, Péter, Lotz, Gábor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558547/
https://www.ncbi.nlm.nih.gov/pubmed/36230493
http://dx.doi.org/10.3390/cancers14194570
_version_ 1784807466696966144
author Kocsmár, Ildikó
Kocsmár, Éva
Pajor, Gábor
Kulka, Janina
Székely, Eszter
Kristiansen, Glen
Schilling, Oliver
Nyirády, Péter
Kiss, András
Schaff, Zsuzsa
Riesz, Péter
Lotz, Gábor
author_facet Kocsmár, Ildikó
Kocsmár, Éva
Pajor, Gábor
Kulka, Janina
Székely, Eszter
Kristiansen, Glen
Schilling, Oliver
Nyirády, Péter
Kiss, András
Schaff, Zsuzsa
Riesz, Péter
Lotz, Gábor
author_sort Kocsmár, Ildikó
collection PubMed
description SIMPLE SUMMARY: The addition of chromosome 17 polysomy/HER2 amplification status to the updated EAU and AUA scores improves their accuracy, allowing molecular reclassification of EAU high-risk NMIBCs and G2 tumors. Based on this, we propose to reclassify the non-HER2 amplified, non-polysomic EAU 3–4 (high- and very high-risk) cases to the EAU 2 (intermediate) risk group to prevent unnecessarily strict follow-up and treatment for these patients. Furthermore, to classify Chr17 polysomic and/or HER2 amplified G2 tumors as high-grade (HG) and non-HER2 amplified, non-polysomic G2 tumors as low-grade (LG) NMIBCs (G1 and G3 tumors remain graded as low- and high-grade, respectively). Thus, the implementation of Chr17 polysomy/HER2 amplification testing would provide an immediate and simple solution to further refine the prognostic risk assessment of NMIBCs in the uro-oncology practice. ABSTRACT: Progression of non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive disease (MIBC) significantly worsens life expectancy. Its risk can be assessed by clinicopathological factors according to international guidelines. However, additional molecular markers are needed to refine and improve the prediction. Therefore, in the present study, we aimed to predict the progression of NMIBCs to MIBC by assessing p53 expression, polysomy of chromosome 17 (Chr17) and HER2 status in the tissue specimens of the tumors of 90 NMIBC patients. Median follow-up was 77 months (range 2–158). Patients with Chr17 polysomy or HER2 gene amplification had a higher rate of disease progression (hazard ratio: 7.44; p < 0.001 and 4.04; p = 0.033, respectively; univariate Cox regression). Multivariable Cox regression models demonstrated that the addition of either Chr17 polysomy or HER2 gene amplification status to the European Association of Urology (EAU) progression risk score increases the c-index (from 0.741/EAU/ to 0.793 and 0.755, respectively), indicating that Chr17 polysomy/HER2 amplification status information improves the accuracy of the EAU risk table in predicting disease progression. HER2/Chr17 in situ hybridization can be used to select non-progressive cases not requiring strict follow-up, by reclassifying non-HER2-amplified, non-polysomic NMIBCs from the high- and very high-risk groups of EAU to the intermediate-risk group.
format Online
Article
Text
id pubmed-9558547
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95585472022-10-14 Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer Kocsmár, Ildikó Kocsmár, Éva Pajor, Gábor Kulka, Janina Székely, Eszter Kristiansen, Glen Schilling, Oliver Nyirády, Péter Kiss, András Schaff, Zsuzsa Riesz, Péter Lotz, Gábor Cancers (Basel) Article SIMPLE SUMMARY: The addition of chromosome 17 polysomy/HER2 amplification status to the updated EAU and AUA scores improves their accuracy, allowing molecular reclassification of EAU high-risk NMIBCs and G2 tumors. Based on this, we propose to reclassify the non-HER2 amplified, non-polysomic EAU 3–4 (high- and very high-risk) cases to the EAU 2 (intermediate) risk group to prevent unnecessarily strict follow-up and treatment for these patients. Furthermore, to classify Chr17 polysomic and/or HER2 amplified G2 tumors as high-grade (HG) and non-HER2 amplified, non-polysomic G2 tumors as low-grade (LG) NMIBCs (G1 and G3 tumors remain graded as low- and high-grade, respectively). Thus, the implementation of Chr17 polysomy/HER2 amplification testing would provide an immediate and simple solution to further refine the prognostic risk assessment of NMIBCs in the uro-oncology practice. ABSTRACT: Progression of non-muscle-invasive bladder cancer (NMIBC) to muscle-invasive disease (MIBC) significantly worsens life expectancy. Its risk can be assessed by clinicopathological factors according to international guidelines. However, additional molecular markers are needed to refine and improve the prediction. Therefore, in the present study, we aimed to predict the progression of NMIBCs to MIBC by assessing p53 expression, polysomy of chromosome 17 (Chr17) and HER2 status in the tissue specimens of the tumors of 90 NMIBC patients. Median follow-up was 77 months (range 2–158). Patients with Chr17 polysomy or HER2 gene amplification had a higher rate of disease progression (hazard ratio: 7.44; p < 0.001 and 4.04; p = 0.033, respectively; univariate Cox regression). Multivariable Cox regression models demonstrated that the addition of either Chr17 polysomy or HER2 gene amplification status to the European Association of Urology (EAU) progression risk score increases the c-index (from 0.741/EAU/ to 0.793 and 0.755, respectively), indicating that Chr17 polysomy/HER2 amplification status information improves the accuracy of the EAU risk table in predicting disease progression. HER2/Chr17 in situ hybridization can be used to select non-progressive cases not requiring strict follow-up, by reclassifying non-HER2-amplified, non-polysomic NMIBCs from the high- and very high-risk groups of EAU to the intermediate-risk group. MDPI 2022-09-21 /pmc/articles/PMC9558547/ /pubmed/36230493 http://dx.doi.org/10.3390/cancers14194570 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kocsmár, Ildikó
Kocsmár, Éva
Pajor, Gábor
Kulka, Janina
Székely, Eszter
Kristiansen, Glen
Schilling, Oliver
Nyirády, Péter
Kiss, András
Schaff, Zsuzsa
Riesz, Péter
Lotz, Gábor
Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer
title Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer
title_full Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer
title_fullStr Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer
title_full_unstemmed Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer
title_short Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer
title_sort addition of chromosome 17 polysomy and her2 amplification status improves the accuracy of clinicopathological factor-based progression risk stratification and tumor grading of non-muscle-invasive bladder cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558547/
https://www.ncbi.nlm.nih.gov/pubmed/36230493
http://dx.doi.org/10.3390/cancers14194570
work_keys_str_mv AT kocsmarildiko additionofchromosome17polysomyandher2amplificationstatusimprovestheaccuracyofclinicopathologicalfactorbasedprogressionriskstratificationandtumorgradingofnonmuscleinvasivebladdercancer
AT kocsmareva additionofchromosome17polysomyandher2amplificationstatusimprovestheaccuracyofclinicopathologicalfactorbasedprogressionriskstratificationandtumorgradingofnonmuscleinvasivebladdercancer
AT pajorgabor additionofchromosome17polysomyandher2amplificationstatusimprovestheaccuracyofclinicopathologicalfactorbasedprogressionriskstratificationandtumorgradingofnonmuscleinvasivebladdercancer
AT kulkajanina additionofchromosome17polysomyandher2amplificationstatusimprovestheaccuracyofclinicopathologicalfactorbasedprogressionriskstratificationandtumorgradingofnonmuscleinvasivebladdercancer
AT szekelyeszter additionofchromosome17polysomyandher2amplificationstatusimprovestheaccuracyofclinicopathologicalfactorbasedprogressionriskstratificationandtumorgradingofnonmuscleinvasivebladdercancer
AT kristiansenglen additionofchromosome17polysomyandher2amplificationstatusimprovestheaccuracyofclinicopathologicalfactorbasedprogressionriskstratificationandtumorgradingofnonmuscleinvasivebladdercancer
AT schillingoliver additionofchromosome17polysomyandher2amplificationstatusimprovestheaccuracyofclinicopathologicalfactorbasedprogressionriskstratificationandtumorgradingofnonmuscleinvasivebladdercancer
AT nyiradypeter additionofchromosome17polysomyandher2amplificationstatusimprovestheaccuracyofclinicopathologicalfactorbasedprogressionriskstratificationandtumorgradingofnonmuscleinvasivebladdercancer
AT kissandras additionofchromosome17polysomyandher2amplificationstatusimprovestheaccuracyofclinicopathologicalfactorbasedprogressionriskstratificationandtumorgradingofnonmuscleinvasivebladdercancer
AT schaffzsuzsa additionofchromosome17polysomyandher2amplificationstatusimprovestheaccuracyofclinicopathologicalfactorbasedprogressionriskstratificationandtumorgradingofnonmuscleinvasivebladdercancer
AT rieszpeter additionofchromosome17polysomyandher2amplificationstatusimprovestheaccuracyofclinicopathologicalfactorbasedprogressionriskstratificationandtumorgradingofnonmuscleinvasivebladdercancer
AT lotzgabor additionofchromosome17polysomyandher2amplificationstatusimprovestheaccuracyofclinicopathologicalfactorbasedprogressionriskstratificationandtumorgradingofnonmuscleinvasivebladdercancer